Favorable Growth Expected At UCB
The Belgian chemical and pharmaceutical company UCB has indicated thatit expects growth this year to be "very favorable" in all three of its product sectors. Executive committee chairman Georges Jacob noted that pharmaceutical sales are increasing in "almost all markets," reflecting the strength of the firm's antiallergy agent Zyrtec (cetirizine).
Zyrtec continues to penetrate the US market, with $95 million in sales for the first four months of this year, compared with $140 million for the US market in 1996. The product is marketed in the USA by Pfizer (see page 5), and was launched in March last year.
The firm is looking at a possible share split, with a view to making shares more accessible to investors. A decision will be made by the end of the year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze